The best characterized resistance mechanism in adult acute myeloid leukemia (AML) is the one mediated by the MDR1 gene which has been shown to be associated with poor outcome. However, alternative proteins such as the more recently recognized multidrug-associated protein (MRP1), may also contribute to the resistance to anthracyclines and etoposide in AML. Recently, the role of this protein was discussed and was unclear in AML. However, recent data concerning the functionality and the modulation of the activity of MRP1 may elucidate its role in comparison with other mechanisms of resistance. In this paper, we will review these recent data concerning the role of MRP1 in adult AML.
Introduction
The use of the first cytostatic agents produced a dramatic improvement in the management of acute myeloid leukemia (AML), but drug resistance eventually arose during chemotherapy. Among different mechanisms of resistance, the appearance of the multidrug resistance (MDR) phenotype is the most frequently observed in many cancer cell lines (including leukemia). The best characterized resistance mechanism is the one mediated by the MDR1 gene which has been shown to be associated with poor outcome. 1 However, alternative proteins such as the multidrug-associated protein (MRP1), may also contribute to the resistance to anthracyclines and etoposide in AML. 2, 3 The role of MRP1 is still being discussed and is unclear in AML. [4] [5] [6] [7] [8] [9] [10] [11] In this paper, we will review recent data concerning the role of MRP1 in adult AML.
Structure and function of MRP1
The MRP1 gene is located on chromosome 16p13.1. MRP1, like Pgp belongs to the ATP binding cassette (ABC) superfamily of membrane transport protein. It is a glycosylated transmembrane protein of 190 kDa. 2 Bakos et al's 12 experiment and the alignment of the MRP1 sequence with the human cystic fibrosis transmembrane conductance (CFTR) suggest that human MRP1 contains a tandem repeat of six transmembrane helices, each followed by a nucleotide binding domain and that the C-terminal membrane-bound region is glycosylated. The N-terminal region of MRP1 contains an additional membrane-bound, glycosylated area with four or five transmembrane helices, which seems to be a characteristic feature of MRP-like ATP-binding cassette transporters.
Transfection experiments with different eukaryotic expression vectors containing full-length complementary DNAs of the MRP1 gene have shown that MRP1 can confer, just like Pgp, resistance to a broad range of natural product drugs among which are doxorubicin, daunorubicin, idarubicin, mitoxantrone and etoposide. 13, 14 At least in transfectants, MRP1 is able to act as an energy-dependent drug pump, mainly localized in the plasma membrane, that extrudes drugs from the cell against a concentration gradient. [14] [15] [16] [17] It has been shown that MRP1 is identical to a GSH-S conjugate carrier described in many cells, because the endogenous leukotriene C4 and other GSH-S conjugates are transported by MRP1. [18] [19] [20] [21] [22] Recently, it was shown that ATP-dependent uptake of the unmodified drug vincristine by membrane vesicles derived from MRP1 transfected HeLa cells is dependent on the presence of GSH. It is possible that GSH interacts directly with MRP1 and that this interaction is necessary for transport. In addition, GSH depletion by buthionine sulphoximine (BSO) increases the accumulation of DNR and Rhodamine 123 (Rh123) in several MRP1-positive cell lines. 21 Therefore, MRP1 is a multiple organic anion transporter, it transports certain glutathione conjugates and may be partly dependent on intracellular glutathione levels for the transport of anthracyclines. Marbeuf-Gueye et al 23 studied the transport kinetics of a series of anthracyclines in tumor cell lines that overexpress MRP1 and Pgp. They showed that the transport kinetics of anthracyclines by MRP1 and Pgp are very similar except for OH-DOX and OH-DNR which had a lower VMax (maximal efflux rate) in the case of MRP1-mediated transport suggesting a role for the amino group in the interaction with glutathione.
On the other hand, Lorico et al 24 compared the sensitivity to chemotherapeutic drugs and toxins of wild-type W9.5 embryonic stem cells and of single and double MRP1 gene knockout cells derived there from. MRP1 expression was totally abrogated in the double knockout cell line and partially abrogated in the single knockout cell line. RT-PCR analyses demonstrated that MDR1 gene was not expressed. The cytotoxic activities of etoposide, teniposide, vincristine, doxorubicin, daunorubicin and sodium arsenite were significantly greater in double knockout cells than in parenteral wild-type ES cells. These findings indicate that baseline MRP1 expression has the capacity to exert a protective role against the toxicity of multiple chemotherapeutic agents and natural toxins. In the same way, deletion of the MRP1 gene was found previously in five of 13 AML patients with inv(16) and was associated with longer overall survival and disease-free survival. 25 This aberration was suggested as being the reason for the better prognosis of patients with inv(16) in this small series of patients. However, lack of MDR1 gene expression might be an alternative explanation for the good prognosis of these patients with inv(16). 25 Zaman et al 26 have shown that in the MRP-overexpressing cell line GLC4/ADR the MRP1 gene copy number is increased about 25-fold, as compared to the parental cell line. However, no AML patients analyzed by Burger et al, 27, 28 including those who had high MRP mRNA expression showed evidence for MRP1 gene amplification. Therefore, they concluded that the increase in MRP1 expression in AML patients was not associated with amplification of the cognate gene.
Ma et al 29 demonstrated that MRP1 is highly phosphorylated and that phosphate groups are metabolically active and undergo cycles of phosphorylation and dephosphorylation in the cell. Serine is the single amino acid phosphorylated in MRP1. The effect of H-7 and staurosporine (two protein kinase inhibitors) can reduce the phosphorylation of this protein. It has also been found that, in the presence of these agents, there is a major increase in drug accumulation and concomitant inhibition in drug efflux of resistant cells. Therefore, certain phosphate groups of protein MRP1 play an important role in modulating drug accumulation in resistant cells.
The DNA containing promoter activity has been sequenced in its entirety and found to contain multiple putative regulatory sites. Studies using a number of different deletion mutants suggest that the major promoter activity of MRP1 resides in a highly GC-rich region of 914 nucleotides (nucleosides −91 to +103). Promoter activity contained within this sequence, however, is modulated by both positive and negative regulatory elements. 30 The functional analysis of the nucleotide binding domains of MRP1 identify several mutations that are critical for MRP-mediated multidrug resistance. 31 Analyses of the subcellular distribution of MRP1 in cell lines revealed that approximatively 80% of MRP1 in the SW-1573 and HeLa transfectants were associated with plasma membrane, while the comparable localization in the drug-selected H69AR cells contained only approximatively 50% of the protein. The remaining MRP1 was codistributed in endocytotic vesicles. The relatively high proportion of MRP1 associated with these fractions in H69AR cells may contribute to the lack of an observable accumulation defect in these cells when compared with the transfectants. 2 In AML cells MRP1 staining (by immunocytochemistery) was primarily cytoplasmic. 32 Several publications have shown that the resistance of cell lines selected by drugs is related to the sequential emergence of MRP1 and MDR1 gene overexpression. At clinically relevant concentrations of doxorubicin or homoharringtonine, in human myeloid leukemia cell lines, the resistance was related to MRP1 overexpression, but not to MDR1 expression. 33, 34 Only when cell lines were exposed to weak concentrations for prolonged time periods or when selected for relatively high-level drugs resistance, did Pgp/MDR1 overexpression become apparent. In the same way, in other cell lines (murine leukemia, small cell lung cancer cells) Pgp expression occurred only in relatively high concentrations of drugs. [35] [36] [37] In the light of these results, MRP1 gene overexpression was probably an early event in the development of drug resistance, and MRP1 and Pgp could be co-expressed in AML cells. These observations suggest that: (1) MRP1 overexpression is probably an early event in the development of drug resistance; (2) drug resistance is usually multifactoral. Therefore, clinical trials which modulate only Pgp might have limited success.
All these data suggest that the role of MRP1 in resistance to chemotherapy, and particularly in AML, need to be considered. Therefore, several studies assessed the expression, function and prognostic value of MRP1 in adult AML. Here we will review all these data.
MRP1 expression in AML
For MDR1 several publications have shown that there was a correlation between Pgp activity and CD34 expression. 38 However, with regard to MRP1 the few results are conflicting and include very few samples. In normal haematopoietic bone marrow CD34 cells, the expression was similar to the basal level in parental HL60 cell line. 39 In contrast, van der Kolk et al 40 found activity of MRP1 in normal CD34 + hematopoietic bone marrow cells, while we have shown that MRP1 activity was higher in CD34 − than in CD34 + leukemia cells.
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Several studies on MRP1 expression in AML have been reported. The incidence of MRP1 gene overexpression in AML patients was obtained by RNA or protein techniques. Messenger RNA was quantified using either RT-PCR or by RNase protection assay. Protein was recently detected by immunocytochemistry, Western blot and flow cytometry with monoclonal antibodies (MRPm6, MRPr1, QRL-1 and QRL-3). 4, [6] [7] [8] 10, 11, 28, [39] [40] [41] [42] [43] All these antibodies recognize an internal epitope of MRP1. 16, 17 Few comparative analyses between these techniques have been published. Filipits et al 44 showed that there was a fair correlation between results obtained with QCRL-1/QCRL-3 and those obtained with MRPr1 by immunocytochemistry for AML patients. In other studies we have demonstrated that three techniques (RT-PCR, in situ hybridation and protein detection by flow cytometry) gave similar results in normal hematopoietic cells and in fresh leukemic cells. 11, 39 Recently, besides MRP1 at least four other homologues of these proteins (these new genes were called MRP2 to MRP5) have been identified. 45 However, MRP3 and MRP5 were only overexpressed in a few cell lines, and the RNA levels did not seem to correlate with resistance to either doxorubicin or cisplatin. MRP4 was not overexpressed in any of the cell lines which were analyzed. MRP2 (or cMOAT) was substantially overexpressed in several cell lines, and MRP2 RNA levels correlate with cisplatin but not doxorubicin resistance in a subset of resistant cell lines. Sequence analysis revealed that the protein segment used to generate the MRPm6 antibody was derived from the most homologous portion located in the Cterminal part of MRP1. In contrast, a more MRP1-specific segment in the N-terminal part of the protein was used for the MRPr1 antibody. According to den Boer et al 46 this may explain the absence of a significant correlation, for 168 children with leukemia, between the fluorescence index using MRPm6 and MRPr1.
The percentage of MRP1 overexpression reported ranged from 7 to 30%. This is difficult to compare because of heterogenous patient populations and techniques (RT-PCR, immunocytochemistry, flow cytometry, Western blot etc), and differences with regard to the definition of overexpression. In addition, only one technique was used and the functionality of MRP1 was not assessed in these studies. 4, [6] [7] [8] 10, 11, 28, 42, 43 For MDR1/Pgp different consensus recommendations showed improved data reproducibility and therefore comparison of results between different studies. [47] [48] [49] For example, these recommendations emphasized the importance of the presentation of data as a continuous variable and the need for multiple techniques to be employed to ensure accurate measurement of Pgp expression. Therefore, as for MDR1/Pgp, we hope that laboratories involved in this area of clinical research will act quickly to develop guidelines for the techniques used to determine the role of MRP1 in the AML resistance to chemotherapy.
On the other hand, in several studies, MRP1 expression was higher in AML at relapse compared to at the time of diagnosis. 4, 6, 7 An analysis of sequential MRP1 expression in 13 patients indicated an increase of expression at relapse in six patients as compared to the time of diagnosis. 8 Schneider et al 6 also showed that, in 62 patients, samples of AML obtained at the time of relapse contained approximatively a two-fold higher level of MRP1. Analysis of 13 paired samples, the first obtained at diagnosis and the second at relapse, showed that MRP1 expression was increased at the time of relapse in more than 80% of patients, 4 in contrast to unchanged level of 7 the incidence of MRP1 gene overexpression tended to be higher in relapsed patients than in newly diagnosed patients (38 vs 18%).
MRP1 activity in AML
In several publications, the expression and function of Pgp did not correlate. 1, 50 For this reason, the functional role appears more informative than the quantification of these proteins in AML samples for this protein. Therefore, as for MDR1, functional MRP1 assays must be used to validate mRNA or protein measurements and to quantify the effect of MRP1 or the magnitude of the effect of a blocker of the MRP1-mediated drug efflux on the intracellular drug concentration.
The majority of data concerning functional tests has been obtained in cell lines and few data are available in clinical AML samples. However, in cancer cell lines, MRP1 activity has been analyzed. Different compounds (Table 1) and modulators (Table 2 ) are available to study MRP1 activity.
Rh123 acts as a fluorescent substrate for Pgp but may also 57 showed that under a 1 h reincubation in drug-free medium, no retention difference of the Rh123 was detected between parenteral and MRP1-expressing resistant cells. But upon extending the reincubation time to 4 h, an efflux of Rh123 in the resistant lines became apparent, and was even more pronounced after 24 h. 57 For Twentyman et al, 53 COR-L23/P and COR-L23/R cell lines accumulated Rh123 at similar rates for the first 30 min, then the curves diverged. For van der Kolk et al, 40 Rh123 was specific in nonhematopoietic cells, but not in hematopoietic cells for studying Pgp-mediated export and could be inhibited by MK571 in hematopoietic cells. However, all these studies involved only cell lines, while in fresh leukemic cells the results are debated. Van der Kolk 40 found that Rh123 was a substrate of MRP1, but we did not. 11 These two studies did not use the same modulators (MK571 and probenecid, respectively). In van der Kolk's study, 40 there was no correlation between MRP1 expression (measured by West-ern blot) and Rh123 efflux-blocking factor of MK-571 even though a correlation was found between MRP1 expression and carboxyfluorescein diacetate (CF) F efflux blocking factor of MK-571.
CF and calcein-acetoxymethylester (calcein-AM) are nonfluorescent compounds, which permeate the plasma membrane, and upon cleavage of the ester bonds by intracellular esterases are transformed into the fluorescent compound which might be a substrate for MRP1 but not for Pgp. 58, 59 Thus, while glutathione may be involved in MRP1-mediated resistance to some chemotherapeutic agents, it is not necessary for the efflux of substrates such as these two compounds. 59, 60 Another substrate, DiOC2 (3), which is a substrate of Pgp, is not a substrate of MRP1. 57 Among some of these compounds are substrates of both MRP1 and Pgp, such as calcein-AM, Rh123, DNR. Although MRP1 has been identified as an organic anion transporter and Pgp as a transporter of certain positively charged compounds, there was considerable overlap in resistance spectrum, suggesting that both proteins transport important anticancer agents in AML treatment such as the anthracyclines and etoposide. Essodaigui et al 61 performed a kinetic analysis of the efflux of calcein-AM, a common neutral substrate for both proteins, and compared it with the kinetics of efflux of calcein, which is only effluxed by MRP1. They showed that calcein is much less efficiently transported by MRP1 than by calcein-AM. Compared to previously published data for anthracyclines, the kinetic data for MRP-mediated calcein-AM pumping are most similar to those for the neutral hydroxydaunorubicin.
In the same way different compounds are available to modulate MRP1 activity (Table 2) . A specific inhibitor of MRP1-mediated transport is MK-571, a leukotriene D4 receptor antagonist. 19 This compound has been shown to increase cytotoxicity of anticancer drugs in a MRP1-positive myeloid leukemic cell line. Probenecid, an inhibitor of organic anion transport, reversed resistance to DNR in a concentrationdependent manner in HL60/AR and H69AR tumor cell lines which overexpressed MRP1. 62 This effect of probenecid was associated with an increased accumulation of DNR and with the correction of the altered subcellular distribution of DNR. The concentration of probenecid that reversed MDR is clinically achievable in vivo, without major toxicity. These results suggest that probenecid is a good modulator for MRP1 activity and a potential candidate for clinical use to reverse MDRassociated MRP1. 62 In contrast, probenecid did not reverse MDR in tumor cell lines which overexpressed Pgp. Probenecid decreased the release of GSH from resistant cells into the medium.
In tumor cell lines, CO-L23/R, GLC4/ADR and MOR/R, which overexpressed MRP1, the resistance to DNR, VCR and Rh123 can be partially reversed by exposing these cells to buthionine sulphoximine (BSO), an inhibitor of glutathione (GSH) synthesis. This effect of BSO on drug resistance was associated with an increased intracellular accumulation of DNR and Rh123, owing to the inhibition of the enhanced drug efflux. In contrast, the accumulation of DNR was not increased in a Pgp-mediated cell line exposed to BSO. In addition, increase of cellular GSH levels in BSO-treated cell lines restored the accumulation deficit of DNR and Rh123, but did not affect calcein or CF accumulation. 59, 60, [63] [64] [65] [66] In the same way, N,N-bis(2-chloroethyl)-N-nitrosourea (BCNU), which decreased intracellular GSH pool by inhibition of the GSH redox cycle, significantly inhibited MRP1-mediated doxorubicin transport and restored intracellular concentrations in vitro in HT1080/DR4 cell line. 67 Another substrate, the diuretic drug ethacrynic acid, which is an efficient inhibitor of glutathione-S-transferases, is a highaffinity substrate and inhibitor of the glutathione-S-conjugate pump associated with MRP1. This implies that ethacrynic acid may modulate drug resistance of tumor cells not only by inhibiting glutathione S-transferase activity, but also by inhibiting the export of drug conjugate from the cell by MRP1. 68 Indomethacin is also reported as a specific inhibitor of MRP1 possibly functioning also by inhibition of glutathione-S-transferase or, alternatively, by direct competition with the drug at the transport site. 69 Pyridine
5(trans-4,6-dimethyl-1,3,2-dioxyaphosphorinan-2-yl)-2,6-dimethyl-4-(3 nitrophenyl)-3-pyridinecarboxylate P-oxide] (PAK-104P) that reverses Pgpmediated MDR, directly interacted with MRP1 and completely reversed the vincristine resistance in MRP1-mediated MDR C-A120 cells. 65, 70 VX-710, a pipecolinate derivate (a novel nonmacrocyclic ligand of the FK-506-binding protein FKBP12) is a potent modulator of Pgp-mediated multidrug resistance, but also affects multidrug resistance in MRP1-expressing cells and may exert its action, at least in part, by binding directly to MRP1. 71 Three newly synthetized imidazothiazole derivatives (N276-12, N276-14 and N276-17) can be useful chemosensitizing agents against MRP1 and Pgp. 72 Other modulators such as genistein, a specific inhibitor of tyrosine kinase, or 7-chloro-4-notrobenz-2-oxa-1,3-diazole (NBD), a vacuolar H+-ATPase, have been reported to modulate MRP1 of a non-specific manner. [73] [74] [75] However, genistein showed major differences in effects on Rh123 vs DNR transport in the MRP1-mediated MDR cell lines: the accumulation of DNR was increased, whereas the accumulation of Rh123 was decreased by genistein. 73 Recently, van der Kolk et al 40 and ourselves 11 have demonstrated that MRP1 was functional in fresh acute myeloid leukemic blast cells using CF and calcein-AM, respectively. We have also seen that some substrates of MRP1 were also substrates of Pgp (calcein-AM, CF, ±Rh123 etc). 76 When the combination of the two inhibitors MRP1 and Pgp was used in the calcein-AM uptake and in the Rh123 efflux assays, a higher blocking factor was observed by van der Kolk et al 40 and ourselves, 11 than when both inhibitors were used separately. Using calcein-AM as substrate and probenecid and CsA as modulator(s) of MRP1 and Pgp, respectively, we have shown in 50 AML patients, that one third of de novo untreated AML exhibited activity of both MRP1 and Pgp, 27% with activity of MRP1 only, 17% with activity of Pgp only and 23% without activity of MRP1 and Pgp (manuscript in preparation).
MRP1 expression and activity as a prognostic factor
The correlation between MRP1 gene expression or activity and treatment outcome is poorly documented in AML. However, in the majority of studies, only one technique was employed and different techniques were used (including RT-PCR, immunocytochemistery, flow cytometry) to measure MRP1 expression. [4] [5] [6] [7] [8] [9] [10] [11] In addition, few studies analyzed the functionality of this protein. Therefore, as for MDR1/Pgp, concensus recommendations and analysis are needed to improving data reproductibility. The results of these studies are summarized in Table 3 . Unfortunately, several of these studies are difficult to compare because of the heterogenous patient populations and the differences regarding the definition of overexpression. Filipits et al 8 did not observe correlations between the level of MRP1 (by immunocytochemistry) and overall survival or DFS of patients. However, the fact that most patients surviving more than 2 years did not express high MRP1 levels warrants additional studies on the association of MRP1 expression of leukemic cells and long-term survival of patients. Zhou et al 7 and Hart et al, 4 using RT-PCR assay, showed that overexpression of MRP1 was a prognostic factor for achievement of CR. In contrast, other studies mentioned that the achievement of CR, duration of remission and overall survival were independent of the level of MRP1 mRNA expression. 5, 6, 9 In 50 patients, we have shown that the combined functionality of MRP1 and Pgp was a prognostic factor for duration of CR and survival, but not MRP1 or Pgp separately (manuscript in preparation). This report suggests that MRP1 and Pgp together need to be considered and that clinical trials that select modulated Pgp are likely to achieve limited success.
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Conclusions
Several experiments have shown that MRP1, as Pgp, also contribute to the resistance to anthracyclines and etoposide in cell lines. However, the role of MRP1 in AML is a question for debate. As for MDR1/Pgp, the major obstacle to definitive conclusions is the difficulty in standardizing techniques. However now, we can assess the functionality of MRP1 and the respective roles of MRP1 and Pgp in fresh leukemic samples. This allows us to elucidate the role of MRP1 as a prognostic factor and as a factor of resistance to chemotherapy in AML in comparison with Pgp. However, as for MDR1/Pgp, it will be important to expand the consensus recommendations to include MRP1.
